[HTML][HTML] NTM drug discovery: status, gaps and the way forward

ML Wu, DB Aziz, V Dartois, T Dick - Drug discovery today, 2018 - Elsevier
Highlights•Incidence of lung disease caused by non-TB mycobacteria (NTM) is
increasing.•Current treatments are ineffective.•There is an urgent need to establish a drug …

Screening of TB actives for activity against nontuberculous mycobacteria delivers high hit rates

JL Low, ML Wu, DB Aziz, B Laleu, T Dick - Frontiers in microbiology, 2017 - frontiersin.org
The prevalence of lung disease due to infections with nontuberculous mycobacteria (NTM)
has been increasing and surpassed tuberculosis (TB) in some countries. Treatment …

Challenges of NTM drug development

JO Falkinham III - Frontiers in microbiology, 2018 - frontiersin.org
Discovery and development of antibiotics active against the environmental opportunistic non-
tuberculous mycobacteria (NTM) have been retarded by innate antibiotic-resistance of NTM …

The Expanding Diversity of Mycobacterium tuberculosis Drug Targets

S Wellington, DT Hung - ACS infectious diseases, 2018 - ACS Publications
After decades of relative inactivity, a large increase in efforts to discover antitubercular
therapeutics has brought insights into the biology of Mycobacterium tuberculosis (Mtb) and …

The challenge of new drug discovery for tuberculosis

A Koul, E Arnoult, N Lounis, J Guillemont, K Andries - Nature, 2011 - nature.com
Tuberculosis (TB) is more prevalent in the world today than at any other time in human
history. Mycobacterium tuberculosis, the pathogen responsible for TB, uses diverse …

[HTML][HTML] Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening

UH Manjunatha, PW Smith - Bioorganic & medicinal chemistry, 2015 - Elsevier
Tuberculosis poses a major global health problem and multi-drug resistant strains are
increasingly prevalent. Hence there is an urgent need to discover new TB drugs. Cell based …

Opportunities for Overcoming Mycobacterium tuberculosis Drug Resistance: Emerging Mycobacterial Targets and Host-Directed Therapy

E Torfs, T Piller, P Cos, D Cappoen - International journal of molecular …, 2019 - mdpi.com
The ever-increasing incidence of drug-resistant Mycobacterium tuberculosis infections has
invigorated the focus on the discovery and development of novel treatment options. The …

Current advances in the clinical development of anti-tubercular agents

SR Tetali, E Kunapaeddi, RP Mailavaram, V Singh… - Tuberculosis, 2020 - Elsevier
Tuberculosis (TB) is a communicable airborne infectious disease caused by the
Mycobacterium tuberculosis (MTB) that primarily affects the lungs, and can disseminate to …

Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis

JC Sacchettini, EJ Rubin, JS Freundlich - Nature Reviews Microbiology, 2008 - nature.com
Tuberculosis (TB) claims a life every 10 seconds and global mortality rates are increasing
despite the use of chemotherapy. But why have we not progressed towards the eradication …

Tuberculosis drug discovery: challenges and new horizons

GFS Fernandes, AM Thompson… - Journal of Medicinal …, 2022 - ACS Publications
Over the past 2000 years, tuberculosis (TB) has claimed more lives than any other infectious
disease. In 2020 alone, TB was responsible for 1.5 million deaths worldwide, comparable to …